Aurobindo Pharma Limited's board of directors has approved a significant restructuring move involving the transfer of its domestic branded generic pharmaceutical formulations products business to its wholly owned subsidiary. The decision was taken at a board meeting held on April 6, 2026, as part of the company's strategic initiative to streamline and accelerate domestic business operations.

Transaction Structure and Consideration

The transfer will be executed through a Business Transfer Agreement (BTA) on a slump sale basis, with the business being transferred as a going concern to Auropharm Limited (previously known as Auro Pharma Limited). The transaction details are structured as follows:

Financial Impact and Business Metrics

The domestic branded generic pharmaceutical formulations business represents a specific portion of Aurobindo Pharma's overall operations. The financial contribution of this business unit demonstrates its focused scope within the company's broader portfolio:

Strategic Rationale and Business Consolidation

The transaction aligns with the group's objective to consolidate domestic pharmaceutical operations under Auropharm Limited, which currently operates the non-oncology formulations business previously acquired from Khandelwal Laboratories Limited. This consolidation strategy aims to enhance operational efficiency and provide a more focused approach toward domestic pharmaceutical business growth.

The transfer encompasses comprehensive business assets including movable assets, employees, contracts, intellectual property, licenses, permits, consents, approvals, trade receivables, inventory, and trade payables. Auropharm Limited is engaged in the business of trade of branded generic formulations and pharmaceutical products in India.

Regulatory and Related Party Considerations

As Auropharm Limited is a wholly owned subsidiary of Aurobindo Pharma Limited, the transaction constitutes a related party transaction under SEBI regulations. However, provisions relating to related party transactions under Section 188 of the Companies Act, 2013 and Regulation 23(5)(b) of SEBI Listing Regulations are not applicable for transactions between a holding company and its wholly owned subsidiary.

The transaction is structured outside the Scheme of Arrangement, though Regulation 37A(1) of SEBI Listing Regulations does not apply as it involves a slump sale rather than the sale of the whole or substantially the whole undertaking. The accounts of Auropharm Limited will continue to be consolidated with the parent company, ensuring no impact on the consolidated financial statements.

Implementation Timeline

The completion of the business transfer is estimated within 90 to 120 days from the date of the Business Transfer Agreement, subject to satisfactory completion of customary conditions precedent. Once completed, the economic benefits of the transferred business will flow to Auropharm Limited effective April 1, 2026. The transaction will not result in any change to the shareholding pattern of Aurobindo Pharma Limited.

Aurobindo Pharma has announced an extension to its timeline for completing the acquisition of up to 26% stake in Swarnaakshu Solar Power Private Limited. The pharmaceutical company informed stock exchanges that the acquisition will now be completed on or before June 30, 2026, subject to receipt of approval from the concerned state government.

Updated Timeline and Regulatory Status

The company has extended its acquisition timeline due to pending receipt of state government approval for setting up a captive solar power plant. This represents a shift from the previously communicated timeline, as the company continues to await necessary regulatory clearances.

Previous Communications

The company has maintained regular communication with stock exchanges regarding this acquisition, with previous letters dated February 6, 2025, March 28, 2025, June 30, 2025, September 26, 2025, and December 30, 2025. The latest update reflects the ongoing regulatory process required for the captive solar power project.

Strategic Solar Investment

The acquisition remains part of the company's renewable energy strategy, involving both a captive solar power purchase agreement and the equity stake in Swarnaakshu Solar. The investment aligns with the pharmaceutical major's commitment to sustainable energy solutions and operational efficiency through renewable energy adoption.